Nakajima H, Hiyama Y, Takamori H, Tsukada W
Research Institute, Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan.
Clin Exp Immunol. 1993 May;92(2):328-35. doi: 10.1111/j.1365-2249.1993.tb03400.x.
We developed a convenient and reliable procedure for the cell-mediated passive transfer of type II collagen (CII)-induced arthritis (CA). Spleen cells from DBA/1 mice with CA were intravenously transferred into syngeneic recipient mice. Arthritis developed only in those recipients which had received whole-body x-irradiation (8 Gy) just before cell transfer and intraperitoneally given soluble CII without adjuvant immediately after transfer. Non-immunized splenocytes could not induce arthritis even in irradiated recipients given soluble CII. Development of arthritis depended on the number of cells transferred; 5 x 10(7) cells induced severe and long-lasting arthritis in every recipient approximately 10 days after transfer. Severity of this arthritis was clinically and histologically similar to classical CA in donors. Arthritogenic splenocytes were generated in donors no later than 20 days after priming with CII in Freund's complete adjuvant, when arthritis had yet to occur, and were detected for more than 5 weeks. One splenocyte population responsible for transferring arthritis was CD4+ T cells. We then applied this system to show that prophylactic treatment of CII-immunized mice with cyclophosphamide (CY, 7 mg/kg), but not interferon-gamma (IFN-gamma, 10(5) U/mouse), suppressed the arthritogenic ability of their spleen cells, although both treatments inhibited the development of CA. Treatment of recipients with IFN-gamma, however, inhibited the development of arthritis upon transfer with CII-immunized splenocytes. These results indicate that CY and IFN-gamma act at the induction and effector phases of arthritogenic lymphocytes, respectively. Thus, this system facilitates investigation of pathological mechanisms of CA, and of mechanisms of anti-arthritics.
我们开发了一种便捷可靠的方法用于细胞介导的II型胶原(CII)诱导性关节炎(CA)的被动转移。将患有CA的DBA/1小鼠的脾细胞静脉注射到同基因受体小鼠体内。关节炎仅在那些在细胞转移前接受过全身X射线照射(8 Gy)且在转移后立即腹腔注射无佐剂可溶性CII的受体小鼠中发生。即使在接受可溶性CII的经照射受体中,未免疫的脾细胞也不能诱导关节炎。关节炎的发生取决于转移的细胞数量;5×10⁷个细胞在转移后约10天能使每个受体诱发严重且持久的关节炎。这种关节炎的严重程度在临床和组织学上与供体中的经典CA相似。致关节炎脾细胞在供体中用弗氏完全佐剂中的CII致敏后不晚于20天产生,此时关节炎尚未发生,并且能被检测到超过5周。一个负责转移关节炎的脾细胞群体是CD4⁺ T细胞。然后我们应用这个系统来表明,用环磷酰胺(CY,7 mg/kg)对CII免疫的小鼠进行预防性治疗,而不是用干扰素-γ(IFN-γ,10⁵ U/小鼠),能抑制其脾细胞的致关节炎能力,尽管两种治疗都抑制了CA的发展。然而,用IFN-γ治疗受体能抑制用CII免疫的脾细胞转移后关节炎的发展。这些结果表明CY和IFN-γ分别作用于致关节炎淋巴细胞的诱导期和效应期。因此,这个系统有助于研究CA的病理机制以及抗关节炎药物的作用机制。